A universal flu vaccine initially developed at Cornell University and now by Versatope Therapeutics will soon be reaching clinical trials, following the awarding of a $17.9 million grant from the National Institute of Allergy and Infectious Diseases. By focusing on the Matrix-2 protein, which is relatively constant among influenza strains, the new vaccine has the potential to last longer and be more effective that existing vaccines. Yourway places great importance on clinical trials with such public health benefits.
Back to Index
6681 Snowdrift Road
Toll Free:
Fax:
Email:
